UCB - Gross Profit On Sales



UCB reported EUR2.46B in Gross Profit on Sales for its fiscal semester ending in December of 2024.


Gross Profit On Sales Change Date
Alcon AG USD 1.39B 5M Jun/2025
Almirall EUR 191.9M 185.49M Mar/2025
Amarin USD 25.13M 1.78M Mar/2025
argenx SE USD 837.21M 127.34M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Bayer EUR 6.38B 1.74B Jun/2025
Galapagos EUR 61.25M 98.68M Mar/2025
Genmab DKK 868M 195M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 692M 64M Dec/2024
Lonza CHF 1.04B 72M Dec/2024
Merck EUR 3.03B 118M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Orion EUR 248.3M 46.5M Jun/2025
Recordati EUR 423.85M 34.92M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
UCB EUR 2.46B 520M Dec/2024
Unibail Rodamco EUR 997M 516.9M Dec/2024